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Hepatobiliary
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ABSTRACT
Background. CheckMate 040 assessed the efﬁcacy and safety
of nivolumab in patients with advanced hepatocellular carcinoma (HCC). Understanding the safety proﬁle of nivolumab is
needed to support the management of treatment-related
adverse events (TRAEs). This analysis assessed the safety
of nivolumab monotherapy in the phase I/II, open-label
CheckMate 040 study.
Materials and Methods. Select TRAEs (sTRAEs; TRAEs with
potential immunologic etiology requiring more frequent
monitoring) occurring between ﬁrst dose and 30 days after
last dose were analyzed in patients in the dose-escalation
and -expansion phases. Time to onset (TTO), time to resolution (TTR), and recurrence of sTRAEs were assessed, and
the outcome of treatment with immune-modulating medication (IMM) was evaluated.
Results. The analysis included 262 patients. The most common sTRAE was skin (35.5%), followed by gastrointestinal

(14.5%) and hepatic (14.1%) events; the majority were grade
1/2, with 10.7% of patients experiencing grade 3/4 events.
One patient had grade 5 pneumonitis. Median (range) TTO
ranged from 3.6 (0.1–59.9) weeks for skin sTRAEs to 47.6
(47.1–48.0) weeks for renal sTRAEs. Overall, 68% of sTRAEs
resolved, with median (range) TTR ranging from 3.7
(0.1–123.3+) weeks for gastrointestinal sTRAEs to 28.4
(0.1–79.1) weeks for endocrine sTRAEs. Most gastrointestinal
and all hepatic events resolved with treatment in accordance
with established toxicity management algorithms. In
57 patients (40%), sTRAEs were managed with IMM.
Reoccurrence of sTRAEs was uncommon following rechallenge
with nivolumab.
Conclusion. Nivolumab demonstrated a manageable safety
proﬁle in this analysis of patients with advanced HCC. A
majority of sTRAEs resolved with treatment. The Oncologist
2020;25:e1532–e1540

Implications for Practice: Nivolumab is a viable treatment option for patients with previously treated advanced hepatocellular carcinoma as it has demonstrated durable tumor responses and promising survival. Nivolumab has a manageable
safety proﬁle. The most common select treatment-related adverse events (sTRAEs) in this analysis were skin related (35%).
Gastrointestinal and hepatic sTRAEs were observed in approximately 14% of patients. The majority of sTRAEs resolved
(68%). Safety events are easier to manage if addressed early. Patient education on signs and symptoms to watch out for
and the importance of early reporting and consultation should be emphasized.
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Figure 1. Hepatic adverse event management algorithm.
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BID, twice daily; CTCAE, Common Terminology
Criteria for Adverse Events; NCI, National Cancer Institute; ULN, upper limit of normal.

INTRODUCTION
Hepatocellular carcinoma (HCC) is the most common cause
of primary liver cancer and the second most common cause
of cancer-related mortality worldwide [1, 2]. HCC is often
diagnosed at an advanced stage, for which effective treatment options are limited [1, 3]. However, even with limited
treatment options, the risks and beneﬁts must be carefully
considered, as most patients with HCC suffer from concomitant cirrhosis and its attendant liver dysfunction.
Immune checkpoint inhibitors, such as programmed cell
death 1 (PD-1) inhibitors, have dramatically improved outcomes
in a variety of cancer types [4]. In patients with advanced HCC
who were previously treated with sorafenib, the international
phase I/II CheckMate 040 study demonstrated that treatment
with the PD-1 inhibitor nivolumab was associated with durable
objective responses (which could have positively impacted survival) and a manageable safety proﬁle [3]. The objective
response rate (ORR) was 15% in the dose-escalation phase and
20% in the dose-expansion phase in patients treated with
nivolumab 3 mg/kg. The 9-month overall survival rates were
66% and 74%, respectively. On the basis of these results,
nivolumab received accelerated approval from the U.S. Food
and Drug Administration for use in patients with HCC who have
been previously treated with sorafenib [5]. Nivolumab was subsequently approved for the same indication in other countries,
including Canada, Taiwan, and Australia [6,7].
Because of their mechanism of action, immune checkpoint
inhibitors are associated with adverse events (AEs) that differ
from those associated with cytotoxic chemotherapy or tyrosine kinase inhibitors. These AEs can affect multiple organ systems and, if moderate or severe, can result in substantial
morbidity and potential mortality [8]. Consequently, early
identiﬁcation and management of treatment-related AEs
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(TRAEs) in patients receiving immune checkpoint inhibitors are
essential to prevent treatment delays and improve outcomes.
The purpose of the current analysis was to assess the safety
proﬁle of nivolumab in the CheckMate 040 study after a
median follow-up of 19.4 months (March 2017 database lock).
Particular attention was paid to select TRAEs (sTRAEs) with an
immunologic etiology, speciﬁcally endocrine, gastrointestinal,
hepatic, pulmonary, renal, and skin sTRAEs. These sTRAEs
require greater awareness from patients and caregivers to
optimize detection and early management.

MATERIALS AND METHODS
Study Design
CheckMate 040 (NCT01658878) was a phase I/II, open-label
study of nivolumab in patients with advanced HCC. The study
consisted of a dose-escalation phase conducted in four countries (U.S., Spain, Hong Kong, and Singapore) and a doseexpansion phase conducted in 11 countries (the four mentioned above plus Canada, U.K., Germany, Italy, Japan, South
Korea, and Taiwan; 39 sites in total). During the doseescalation phase, sequential groups of patients received intravenous (IV) nivolumab 0.1 mg/kg, 0.3 mg/kg, 1.0 mg/kg, 3.0
mg/kg, or 10.0 mg/kg every 2 weeks in a 3 + 3 design. During
the dose-expansion phase, all patients received nivolumab 3.0
mg/kg IV every 2 weeks. Ongoing randomized phases of
CheckMate 040 include additional treatment arms (including
nivolumab in combination with ipilimumab and/or cabozantinib);
however, because these fall outside the remit of this safety
analysis, they will be discussed in a future study. The primary
study objectives were to assess safety and tolerability in the
dose-escalation phase and ORR in the dose-expansion phase.
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Table 1. Summary of sTRAEs by CTCAE grade
On treatmenta (N = 262)

Treatment discontinuedb (N = 226)

sTRAEs

Any grade, n (%)

Grade 3/4, n (%)

Any grade, n (%)

Grade 3/4, n (%)

Total patients with ≥1 sTRAEc

143 (54.6)

28 (10.7)

35 (15.5)

13 (5.8)

Skin

93 (35.5)

5 (1.9)

12 (5.3)

2 (0.9)

Pruritus

56 (21.4)

1 (0.4)

7 (3.1)

1 (0.4)

Rash

46 (17.6)

2 (0.8)

2 (0.9)

0

9 (3.4)

0

1 (0.4)

0

Erythema

3 (1.1)

1 (0.4)

1 (0.4)

0

Rash pruritic

3 (1.1)

0

1 (0.4)

0

Psoriasis

3 (1.1)

1 (0.4)

2 (0.9)

1 (0.4)

Skin exfoliation

2 (0.8)

0

0

0

Rash papular

2 (0.8)

0

0

0
0

Rash maculopapular

Eczema

1 (0.4)

0

0

Dermatitis

1 (0.4)

0

0

0

Palmar-plantar erythrodysesthesia syndrome

1 (0.4)

0

0

0

Rash erythematosus

1 (0.4)

0

0

0

Skin hypopigmentation

1 (0.4)

0

0

0

38 (14.5)

3 (1.1)

3 (1.3)

1 (0.4)
1 (0.4)

Gastrointestinal
Diarrhea

36 (13.7)

3 (1.1)

3 (1.3)

Colitis

2 (0.8)

1 (0.4)

0

0

Enteritis

1 (0.4)

0

0

0

Frequent bowel movements
Hepatic

1 (0.4)

0

0

0

37 (14.1)

17 (6.5)

13 (5.8)

7 (3.1)

AST increased

26 (9.9)

14 (5.3)

7 (3.1)

4 (1.8)

ALT increased

25 (9.5)

9 (3.4)

6 (2.7)

4 (1.8)

Blood bilirubin increased

7 (2.7)

1 (0.4)

4 (1.8)

0

Blood alkaline phosphatase increased

6 (2.3)

0

1 (0.4)

0

Hyperbilirubinemia

3 (1.1)

0

2 (0.9)

0

Hepatitis

1 (0.4)

1 (0.4)

2 (0.9)

2 (0.9)

Liver disorder

1 (0.4)

0

1 (0.4)

0

Gamma-glutamyltransferase increased

1 (0.4)

1 (0.4)

0

0

Liver function test increased

1 (0.4)

1 (0.4)

1 (0.4)

1 (0.4)

25 (9.5)

2 (0.8)

3 (1.3)

2 (0.9)

Endocrine disorders

16 (6.1)

1 (0.4)

0

0

Hypothyroidism

10 (3.8)

0

1 (0.4)

0

Hyperthyroidism

2 (0.8)

0

0

0

Adrenal insufﬁciency

2 (0.8)

1 (0.4)

1 (0.4)

1 (0.4)

Endocrine

Secondary adrenocortical insufﬁciency

1 (0.4)

0

0

0

Autoimmune hypothyroidism

1 (0.4)

0

0

0

Autoimmune thyroiditis

1 (0.4)

0

0

0

7 (2.7)

0

0

0

Blood TSH increased

5 (1.9)

0

0

0

Blood TSH decreased

2 (0.8)

0

0

0

2 (0.8)

1 (0.4)

0

0

2 (0.8)

1 (0.4)

1 (0.4)

1 (0.4)

3 (1.1)

1 (0.4)

4 (1.8)

2 (0.9)

3 (1.1)

1 (0.4)

4 (1.8)

2 (0.9)

2 (0.8)

0

1 (0.4)

0

Blood creatinine increased

2 (0.8)

0

0

0

Autoimmune nephritis

0

0

1 (0.4)

0

Investigations

Metabolism and nutrition disorders
Diabetes mellitus
Pulmonary
Pneumonitisd
Renal

Events reported between ﬁrst dose and 30 days after last dose of nivolumab.
b
Events reported between last dose of nivolumab and 100 days after last dose.
c
Patients may have experienced sTRAEs in multiple categories.
d
One case of grade 5 pneumonitis occurred more than 30 days after last day of treatment.
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; CTCAE, Common Terminology Criteria for Adverse Events;
sTRAE, select treatment-related adverse event; TSH, thyroid-stimulating hormone.
a

© 2020 The Authors.
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Figure 2. Time to onset (TTO) of any-grade sTRAEs. TTO was deﬁned as the time between the ﬁrst dose of study treatment and
onset of earliest sTRAE in the category. Data are presented as medians with interquartile range (boxes) and range (bars).
Abbreviations: IQR, interquartile range; sTRAE, select treatment-related adverse event.

Table 2. Summary of IMM for any-grade sTRAEs
sTRAEs
Total patients with ≥1 sTRAEb (n = 143)
Skin (n = 93)
Topical corticosteroidsc
Systemic corticosteroidsd
Cyclosporine
Ophthalmologic medication
Gastrointestinal (n = 38)
Systemic corticosteroidsd
Hepatic (n = 37)
Systemic corticosteroidsd
Mycophenolic acid
Endocrine (n = 25)
Systemic corticosteroidsd
Pulmonary (n = 3)
Systemic corticosteroidsd
Renal (n = 2)

Patients receiving
IMM, n/n (%)
57/143 (39.9)
41/93 (44.1)
38/93 (40.9)
4/93 (4.3)
1/93 (1.1)
2/93 (2.2)
6/38 (15.8)
6/38 (15.8)
7/37 (18.9)
7/37 (18.9)
1/37 (2.7)
3/25 (12.0)
3/25 (12.0)
2/3 (66.7)
2/3 (66.7)
0/2 (0.0)

Patients with resolutiona
of sTRAEs after IMM, n/n (%)
41/57 (71.9)
27/41 (65.9)

5/6 (83.3)

Median TTR after
IMM (range), wk
18.1 (0.1–88.3+)
20.7 (0.1–88.3+)

5.1 (1.6–31.6+)

7/7 (100.0)

19.4 (2.4–35.9)

2/3 (66.7)

30.1 (0.4–38.3+)

1/2 (50.0)

NA (0.6–70.9+)

a

Resolution was deﬁned as complete resolution or improvement to baseline grade.
Patients may have experienced sTRAEs in multiple categories.
c
Includes topical betamethasone, clobetasol, dexamethasone, ﬂuocinolone, ﬂuocinonide, hydrocortisone, methylprednisolone, mometasone,
prednicarbate, and triamcinolone.
d
Includes systemic budesonide, dexamethasone, hydrocortisone, methylprednisolone, prednisolone, and prednisone.
Abbreviations: IMM, immune-modulating medications; NA, not achieved; sTRAE, select treatment-related adverse event; TTR, time to
resolution.
b

Full details of the study design and results have been
reported previously [3].

have Child-Pugh scores of 7 or less for the dose-escalation
phase and scores of 6 or less for the dose-expansion phase.
Full eligibility criteria have been reported previously [3].

Patients
Adults with histologically conﬁrmed, advanced HCC not
amenable to curative resection were eligible for the study.
Patients could be either sorafenib naive or experienced
(progressed on or intolerant of sorafenib) and were eligible
irrespective of hepatitis C virus or hepatitis B virus (HBV)
status; patients with HBV were required to have an HBV
DNA level less than 100 IU/mL. Patients were required to

www.TheOncologist.com

Safety Assessments
Safety was assessed between the ﬁrst dose and up to 100 days
after the last dose of nivolumab. The analysis of TRAEs included
events occurring between the ﬁrst dose and 30 days after the
last dose of study therapy, or until all TRAEs were resolved
(complete resolution or improvement to baseline grade) or
deemed irreversible by the investigator. For sTRAEs (AEs with a

© 2020 The Authors.
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Figure 3. Time to resolution (TTR) of any-grade sTRAEs. TTR was deﬁned as the longest time from onset to complete resolution or
improvement to baseline grade. Data are presented as medians with interquartile range (boxes) and range (bars).
Abbreviations: IQR, interquartile range; NA, not achieved; sTRAE, select treatment-related adverse event.

potential inﬂammatory mechanism requiring more frequent
monitoring and/or unique intervention such as immunosuppressants and/or endocrine replacement therapy), the time to
onset (TTO; deﬁned as the time between the ﬁrst dose of study
treatment and the earliest onset of sTRAE in the category) and
time to resolution (TTR; deﬁned as the longest time from sTRAE
onset to complete resolution or improvement to baseline
grade) were recorded. For patients with dose delays due to
sTRAEs, all sTRAEs occurring after resumption of nivolumab
were documented. The reoccurrence of sTRAEs in patients who
received nivolumab following the onset and resolution of an initial sTRAE (rechallenge) was also recorded. Medications used to
manage the sTRAEs and whether the medications led to resolution of the sTRAEs were also evaluated. All sTRAEs were graded
using National Cancer Institute (NCI) Common Terminology
Criteria for Adverse Events (CTCAE) version 4.0.

Management of Select Treatment-Related Adverse
Events
Select TRAEs were managed using protocol-speciﬁed algorithms, which included the use of immune-modulating medication (IMM) [9]. The algorithm for management of hepatic
sTRAEs was modiﬁed from the nivolumab development program algorithm to account for potential baseline abnormalities in liver function, which are common in patients with
HCC. In this modiﬁed algorithm (Fig. 1), aspartate aminotransferase (AST)/alanine aminotransferase (ALT) monitoring
was recommended to be performed every 3 days for
patients with hepatic AEs. Nivolumab doses were
recommended to be delayed when a two-grade shift of
AST/ALT levels from a baseline event of grade 0 or 1 was
observed (based on NCI CTCAE criteria). For patients with
baseline AST or ALT within the grade 2 toxicity range, doses
had to be delayed for increases in AST or ALT at 2 × baseline
value or when AST or ALT was 8 × upper limit of normal
(ULN; whichever was lower). Corticosteroid treatment had to
be initiated when a dose delay of 3–5 days did not improve
AST/ALT levels or when AST/ALT levels exceeded 8 × ULN.
Nivolumab treatment could be resumed when AST/ALT

returned to near baseline levels, provided the criteria for discontinuation had not been met.

Statistical Analyses
Statistical analyses of safety data were purely descriptive;
sTRAEs were tabulated by frequency and severity and by system
organ class and preferred term. The current analysis includes
data from all patients in the intent-to-treat population.

Study Oversight
This study was approved by the institutional review board
or independent ethics committee at each participating center and was conducted in accordance with Good Clinical
Practice guidelines, as deﬁned by the International Council
on Harmonisation, and with the principles of the Declaration of Helsinki. All patients provided written informed consent prior to enrollment.

RESULTS
Patients
A total of 262 sorafenib-naive or -experienced (progressed on
or intolerant of sorafenib) patients were included in the
intent-to-treat population, with 48 treated in the doseescalation phase and 214 in the dose-expansion phase.
Median age was 63 years, and 98.5% of patients had a ChildPugh score of 5–6 (class A). Eastern Cooperative Oncology
Group performance status was 0 or 1 for all patients. Patients
received nivolumab treatment for a median of 4.9 months
(range, 0–37.4+): 162 patients (61.8%) were treated for more
than 3 months, and 27 patients (10.3%) were treated for longer than 18 months. At database lock in March 2017, the
median duration of follow-up for the overall population was
19.4 months (range, 16.2–51.7).

Safety
Select TRAEs occurred in 143 patients (54.6%), and grade
3/4 sTRAEs occurred in 28 patients (10.7%). Ten patients
(6.8%) were hospitalized (or had hospitalization prolonged)

© 2020 The Authors.
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because of sTRAEs. The most frequently reported sTRAEs
were skin (35.5% of patients), gastrointestinal (14.5%), and
hepatic (14.1%; Table 1). The most common skin sTRAEs
were pruritus (21.4%) and rash (17.6%), whereas diarrhea
(13.7%) was the most common gastrointestinal sTRAE. Elevations of ALT and AST were the most common hepatic
sTRAEs, occurring in 25 (9.5%) and 26 patients (9.9%),
respectively. The most frequent grade 3/4 sTRAEs were
hepatic AEs (6.5%). Grade 3/4 elevations of ALT and AST
occurred in 3.4% and 5.3% of patients, respectively. Generally, safety proﬁles were similar across the different etiologies of HCC (data not shown).
Over 100 days of follow-up after the last dose of
nivolumab, 35 of 226 (15.5%) patients had an sTRAE, of
which 13 patients (5.8%) had a grade 3/4 event. The most
common any-grade sTRAEs reported after treatment discontinuation were AST increased (3.1% of patients), pruritus
(3.1%), ALT increased (2.7%), pneumonitis (1.8%), blood bilirubin increased (1.8%), and diarrhea (1.3%; Table 1). One
patient died of an sTRAE (grade 5 pneumonitis) that occurred
more than 100 days after discontinuation of nivolumab
because of disease progression and after subsequent treatment with sorafenib. This event was considered by investigators to be related to both nivolumab and sorafenib
treatment.
The TTOs of sTRAEs (any grade) are shown in Figure 2.
With the exception of endocrine AEs, sTRAEs generally
occurred within the ﬁrst 4–12 weeks of nivolumab treatment. The median (range) TTO ranged from 3.6 (0.1–59.9)
weeks for skin sTRAEs to 47.6 (47.1–48.0) weeks for renal
sTRAEs. The median (range) TTO of endocrine and hepatic
sTRAEs was 18.3 (2.0–71.0) weeks and 6.0 (0.1–57.1) weeks,
respectively.
A summary of IMM used to treat any-grade sTRAEs is
shown in Table 2. Overall, 57 patients (39.9%) with sTRAEs
received IMM; sTRAEs resolved after IMM treatment in
41 patients (71.9%). Of the 57 patients who received IMM
for an sTRAE, 11 progressed; the median (range) time to
progression after IMM use was 10.4 (1–88) weeks.
The most common sTRAE category for which patients
received IMM treatment was skin, with 41 of 93 patients
(44.1%) receiving IMM. However, proportionally, the highest
rate of IMM use was for pulmonary AEs, with two-thirds of
patients (66.7%) receiving IMM. Across all sTRAE categories,
the majority of patients requiring IMM therapy received
corticosteroids. For skin sTRAEs, 38 of 93 patients (40.9%)
received topical corticosteroids, and 4 of 93 (4.3%) received
systemic corticosteroids; cyclosporine (1/93; 1.1%) was also
used for the treatment of skin sTRAEs. Systemic corticosteroids were the only treatment used for gastrointestinal
(6/38 patients; 5 resolved), endocrine (3/25; 2 resolved),
and pulmonary (2/3; 1 resolved) sTRAEs. Seven of 37 patients
who experienced a hepatic sTRAE received systemic corticosteroids (all resolved), of which 1 patient also received
mycophenolic acid for a grade 4 ALT elevation (the event
resolved 3 days after treatment).
Gastrointestinal sTRAEs resolved the fastest, whereas
endocrine sTRAEs resolved the slowest. The median (range)
time to resolution of any-grade sTRAEs ranged from 3.7
(0.1–123.3+) weeks for gastrointestinal events to 28.4 (0.1–
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Table 3. Summary of sTRAEs leading to dose delay,
according to worst CTCAE grade
N = 262
sTRAEs
Total patients with ≥1 sTRAE
leading to dose delaya
Skin (n = 93)
Pruritus
Rash
Erythema
Psoriasis
Gastrointestinal (n = 38)
Diarrhea
Colitis
Hepatic (n = 37)
AST increased

Any grade,
n (%)
30 (11.5)

Grade 3/4,
n (%)
16 (6.1)

6 (6.5)
2 (2.2)

4 (4.3)
1 (1.1)

2 (2.2)
1 (1.1)
1 (1.1)
6 (15.8)
5 (13.2)
1 (2.6)
14 (37.8)
10 (27.0)

1 (1.1)
1 (1.1)
1 (1.1)
1 (2.6)
0
1 (2.6)
9 (24.3)
8 (21.6)

ALT increased
Blood bilirubin increased
Blood alkaline phosphatase
increased
Hepatitis
Liver disorder
Endocrine (n = 25)
Hypothyroidism
Adrenal insufﬁciency
Diabetes mellitus
Pulmonary (n = 3)

7 (18.9)
2 (5.4)
1 (2.7)

4 (10.8)
0
0

1 (2.7)
1 (2.7)
3 (12.0)
1 (4.0)
1 (4.0)
1 (4.0)
1 (33.3)

1 (2.7)
0
2 (8.0)
0
1 (4.0)
1 (4.0)
0

Pneumonitis
Renal (n = 2)
Blood creatinine increased

1 (33.3)
1 (50.0)
1 (50.0)

0
0
0

a

Patients may have experienced sTRAEs in multiple categories.
Includes events reported between ﬁrst dose and 30 days after last
dose of study therapy.
Dose delay was deﬁned as a delay exceeding 3 days and determination of dose delay was based on investigator assessment. Percentages are calculated based on total numbers of patients having a
sTRAE in the category.
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; sTRAE, select treatment-related adverse event.

79.1) weeks for endocrine events (Figure 3). Resolution
times (range) for any-grade sTRAEs that occurred most frequently in skin, gastrointestinal, and hepatic categories
were 23.1 (0.1–143.9+) weeks for pruritus, 7.0 (0.1–64.3+)
for rash, 3.6 (0.1–123.3+) for diarrhea, 4.2 (0.7–71.1+) for
AST increased, and 8.1 (2.0–69.9+) for ALT increased. The
time to resolution for hypothyroidism (the most common
endocrine sTRAE) ranged from 3.0+ to 79.1+ weeks (the
median could not be estimated). The percentage of sTRAEs
(any grade) that resolved after a median follow-up of
19.4 months ranged from 50.0% (1/2 AEs) for renal sTRAEs
to 78.4% (29/37 AEs) for gastrointestinal sTRAEs. For grade
3/4 sTRAEs, the corresponding resolution rates ranged from
50% (1/2 AEs) for endocrine sTRAEs to 100% (1/1 AE) for
pulmonary sTRAEs. For hepatic sTRAEs, the resolution rates
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Table 4. Summary of sTRAE reoccurence in patients who
were rechallenged with nivolumab

sTRAEs
Hepatic
Skin
Gastrointestinal
Endocrine
Renal
Pulmonary

Patients rechallenged
after resolution
of sTRAE, n
18
39
26
10
0
0

Reoccurrence
of any-grade
sTRAE n (%)
2 (11.1)
0
0
0
0
0

Rechallenge occurred when the last nivolumab infusion was administered after the onset of an sTRAE. Includes events reported within
30 days after last dose of study therapy. Recurrent was deﬁned as
an event that reoccurred on or after rechallenge.
Abbreviation: sTRAE, select treatment-related adverse event.

were 70.3% (26/37 AEs) for any-grade sTRAEs and 88.2%
(15/17 AEs) for grade 3/4 sTRAEs.
The median (range) TTR for sTRAEs treated with IMM
ranged from 5.1 (1.6–31.6+) weeks for gastrointestinal events to
30.1 (range 0.4–38.3+) weeks for endocrine events (Table 2).
Table 3 shows sTRAEs leading to dose delay. Overall,
30 (11.5%) patients had sTRAEs that led to a delay in treatment; 16 (6.1%) of these patients had grade 3/4 sTRAEs.
Hepatic sTRAEs were the most common cause of dose delays,
occurring in 14 of 37 (37.8%) patients with any-grade hepatic
sTRAEs. The most frequent grade 3/4 sTRAEs leading to dose
delay were elevations in AST (21.6%) and ALT (10.8%).
Reoccurrence of sTRAEs in patients who received
nivolumab following resolution of the initial event (rechallenge)
was low (Table 4). Of the 18 patients who were rechallenged
with nivolumab following a hepatic sTRAE, 2 (11.1%) had a
reoccurring event (Table 4). No other sTRAEs reoccurred following rechallenge.

DISCUSSION
Data from the dose-escalation and -expansion cohorts of
CheckMate 040 indicate that the safety proﬁle of nivolumab,
based on sTRAEs, in sorafenib-naive or -experienced patients
with advanced HCC is generally consistent with the safety proﬁles of nivolumab in other tumor types, including unresectable
or metastatic melanoma, metastatic non-small cell lung cancer,
advanced renal cell carcinoma, Hodgkin lymphoma, squamous
cell carcinoma of the head and neck, advanced or metastatic
urothelial carcinoma, and colorectal cancer [5]. Hepatic sTRAEs
occurred at a higher frequency in the current patient population; however, these events were reversible and manageable
and rarely led to treatment discontinuation. No new safety signals emerged during a median follow-up of 19.4 months.
Around half of all patients experienced an sTRAE
(~55%). This highlights the importance of educating patients
on potential AEs to encourage earlier reporting that could
facilitate better management. It is encouraging that most
sTRAEs were mild (i.e., grade 1/2).
In general, sTRAEs occurred within the ﬁrst 4–12 weeks of
treatment; it is particularly important for the patient and

caregivers to pay attention to signs and symptoms of potential
AEs during this period. Time to onset varied by category. Skin
sTRAEs occurred earliest (within 1 month of treatment initiation); gastrointestinal, hepatic, and pulmonary sTRAEs were
commonly observed within the ﬁrst 3 months of treatment.
Endocrine and renal sTRAEs occurred later. It is important that
the management of any AE begins with ruling out other,
nondrug-related causes. However, signs and symptoms within
speciﬁc time periods could indicate a nivolumab-related event.
Of note, sTRAEs for all categories were observed past the
range of 4–12 weeks, emphasizing the need for continued vigilance during treatment. Recently published evidence-based
guidelines for the management of immune-related AEs in
patients receiving immune checkpoint inhibitors emphasize
the importance of counseling patients to be aware of potential immune-related AEs and the importance of taking appropriate action [8].
For sTRAEs, skin events were the most common,
followed by gastrointestinal and hepatic events. Skin sTRAEs
are of special interest as skin AEs, particularly hand-foot
skin reaction (HFSR), are of clinical concern with the use of
sorafenib. Prior to the introduction of nivolumab, the oral
multikinase inhibitor sorafenib was the ﬁrst evidence-based
treatment option approved for patients with advanced HCC
and is currently considered the standard of care [10, 11]. In
pivotal sorafenib trials, HFSR of any grade was reported in
21% and 45% of patients in predominantly Western and
Asian populations, respectively [12, 13]. HFSR usually presents with a range of symptoms from burning, tingling, and
skin erythema to pain, edema, and ulcerations in the
extremities; HFSR can interfere with simple daily activities,
such as walking or gripping objects [14, 15]. Based on current study data, skin sTRAEs may be the ﬁrst AEs that
patients experience following initiation of nivolumab treatment, often developing within the ﬁrst month. However, in
contrast to sorafenib, skin sTRAEs with nivolumab are commonly pruritus (21.4%) and rash (17.6%). Rash AEs were
mostly mild, with <1% frequency of grade 3/4 events. Skin
sTRAEs were manageable and resolved in 63.2% of patients
after treatment with topical corticosteroids.
Because patients with advanced HCC already have
hepatic morbidity, the incidence and severity of hepatic
sTRAEs with nivolumab treatment are important considerations [16]. The low incidence of any-grade (14.1%) and
grade 3/4 (6.5%) hepatic sTRAEs in CheckMate 040 is therefore encouraging. Similarly, the incidence of gastrointestinal
sTRAEs was low (14.5%), with a low rate of grade 3/4
events (1.1%). Diarrhea accounted for 13.7% of gastrointestinal sTRAEs, whereas colitis was uncommon (<1%).
Many patients (39.9%) who experienced sTRAEs were
treated with IMM, according to the relevant AE management algorithm. Immune-related AEs potentially require
the use of IMM such as steroids. Clinicians should therefore
rule out other potential causes of the AE; for example,
treating diarrhea or pneumonitis from an infection with steroids is unwarranted and risky [17]. A second important
aspect of clinical management is to taper steroids slowly
over at least a month. There is a risk of rebound if steroids
are tapered too quickly, and steroid withdrawal should be
gradual, according with standard medical practice [8].
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The general approach for management of hepatic events
with nivolumab was based on cumulative data across tumor
types in patients with normal hepatic function. To account for
potential baseline liver dysfunction in patients with HCC, a
modiﬁed algorithm with adjusted upper limits for inclusion was
used in CheckMate 040 for the management of hepatic sTRAEs.
It is encouraging to note that only 7 of 37 patients with hepatic
sTRAEs required treatment with IMM (primarily steroids),
suggesting that nivolumab-related hepatic sTRAEs are manageable, even in patients with underlying liver dysfunction.
Reoccurrence of sTRAEs was uncommon. In patients
who were rechallenged with nivolumab, the initial sTRAE
only reoccurred in two patients, both of whom experienced
hepatic events. Most sTRAEs requiring treatment were
effectively managed by systemic corticosteroids.
Select TRAEs commonly resolved in 4–12 weeks following
dose delays or treatment with an IMM. Endocrine sTRAEs
may be resolved with low doses of systemic corticosteroids
[8], provided that patients are compliant with this therapy. In
such cases, regular monitoring of cortisol levels is useful.
Some endocrine sTRAEs, however, may not completely
resolve. For example, thyroid AEs such as hypothyroidism
could require lifetime hormone supplementation [17, 18].
The TTR of sTRAEs is variable, and the management of
each patient must be individualized. Nivolumab management
guides provide recommendations for monitoring and managing sTRAEs [19]. Many other practical recommendations and
guidelines are also available for health care professionals.
In CheckMate 040, nivolumab led to durable responses
and clinically meaningful survival and had a manageable
safety proﬁle in an etiologically diverse population of
patients with advanced HCC [3]. Furthermore, the hepatic
sTRAEs often seen in patients with cirrhosis were readily
manageable. These efﬁcacy and safety data suggest that
nivolumab has the potential to improve outcomes for
patients with advanced HCC.
Limitations of the current study include the nonrandomized design of the CheckMate 040 cohorts analyzed.
More information on the safety of nivolumab has been provided by the CheckMate 459 study, a randomized phase III trial
of nivolumab versus sorafenib as ﬁrst-line treatment in
patients with advanced HCC (ClinicalTrials.gov: NCT02576509)
[20]. Although data are limited for patients with Child-Pugh
scores of 7 or higher (class B or C), the safety of nivolumab has
been evaluated in this population as part of the CheckMate
040 trial [21], and more data from this cohort are forthcoming.

CONCLUSION
In this safety analysis of sorafenib-naive or -experienced
patients with advanced HCC, nivolumab demonstrated a
manageable safety proﬁle. Treatment with nivolumab was

generally well tolerated. TRAEs, other than endocrine
events, generally occurred early in treatment. A majority of
sTRAEs, including hepatic events, resolved with dose delays
and with the addition of IMM in a subset of patients.
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